Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

Trial Profile

Phase 1/2 Study of Lenvatinib in Children and Adolescents With Refractory or Relapsed Solid Malignancies and Young Adults with Osteosarcoma

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jun 2018

At a glance

  • Drugs Lenvatinib (Primary) ; Etoposide; Ifosfamide
  • Indications Osteosarcoma; Solid tumours; Thyroid cancer
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Eisai Co Ltd
  • Most Recent Events

    • 05 Jun 2018 Results reporting data from Phase 2 single-agent LEN expansion cohort and Phase 1b combination dose-finding cohort of LEN + ETP + IFM in patients with relapsed/refractory osteosarcoma presented at the 54th Annual Meeting of the American Society of Clinical Oncology
    • 10 Jun 2017 Biomarkers information updated
    • 02 Jun 2017 Results (n=23) from the single-agent lenvatinib dose-finding part of a phase 1/2 study in children and adolescents with solid tumors presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top